Loading…
Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer
Purpose The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer (BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival. Methods In a well-characterized cohort of 305 primary BC, subcellular d...
Saved in:
| Published in: | Journal of cancer research and clinical oncology 2021-09, Vol.147 (9), p.2535-2544 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133 |
| container_end_page | 2544 |
| container_issue | 9 |
| container_start_page | 2535 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 147 |
| creator | Shao, Wanting Kuhn, Christina Mayr, Doris Ditsch, Nina Kailuwait, Magdalena Wolf, Verena Harbeck, Nadia Mahner, Sven Jeschke, Udo Cavaillès, Vincent Sixou, Sophie |
| description | Purpose
The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer (BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival.
Methods
In a well-characterized cohort of 305 primary BC, subcellular distribution of LXR was evaluated by immunohistochemistry. Correlations with clinicopathological characteristics as well as with patient outcome were analyzed.
Results
LXR was frequently localized in both nuclei and cytoplasms of BC cells, with stronger staining in nuclei. Total and nuclear LXR expression was positively correlated with ER and PR status. Overall survival analysis demonstrated that cytoplasmic LXR was significantly correlated with poor survival and appeared as an independent marker of poor prognosis, in stage I but not in stage II–III tumors
Conclusion
Altogether, these data suggest that cytoplasmic LXR could be defined as a prognostic marker in early stage primary BC. |
| doi_str_mv | 10.1007/s00432-021-03670-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8310839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2537642104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133</originalsourceid><addsrcrecordid>eNp9Uk2P0zAQtRCILYU_wMkSFzgE_BHHzgVpVS27SJWQEEjcLNeZtFlSO9jpLvn3TEgFYg9cxpqZ957H40fIS87ecsb0u8xYKUXBBC-YrDQrpkdkxecSl1I9JivGNS-U4NUFeZbzLcNcafGUXMiSGcVqsyLTZhrj0Lt87DzdfvtM4eeQIOcuBtpl6jCGBgbAEEZ6dOk7JBpbOsSY6JDiPsSMuHbO3NghKNP7bjxQcKmfaB7dHhDXIXOiuwQuj9S74CE9J09a12d4cT7X5OuHqy-bm2L76frj5nJb-NKosdhVui4V87xqoC7LWjSVdKLyXLiGgdMMX1WZFrCvhDECytYJ5z1ItdM1LmJN3i-6w2l3hMbjiMn19jyTja6z_3ZCd7D7eGeN5MzIGgXeLAKHB7Sby62dawy3bZRmdxyxr8-XpfjjBHm0xy576HsXIJ6yFUrqqhQcP25NXj2A3sZTCrgKRKnS1JXWs6BYUD7FnBO0fybgzM4usIsLLLrA_naBnZAkF1JGcNhD-iv9H9YvvGm1Vw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554896771</pqid></control><display><type>article</type><title>Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer</title><source>Springer Nature</source><creator>Shao, Wanting ; Kuhn, Christina ; Mayr, Doris ; Ditsch, Nina ; Kailuwait, Magdalena ; Wolf, Verena ; Harbeck, Nadia ; Mahner, Sven ; Jeschke, Udo ; Cavaillès, Vincent ; Sixou, Sophie</creator><creatorcontrib>Shao, Wanting ; Kuhn, Christina ; Mayr, Doris ; Ditsch, Nina ; Kailuwait, Magdalena ; Wolf, Verena ; Harbeck, Nadia ; Mahner, Sven ; Jeschke, Udo ; Cavaillès, Vincent ; Sixou, Sophie</creatorcontrib><description>Purpose
The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer (BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival.
Methods
In a well-characterized cohort of 305 primary BC, subcellular distribution of LXR was evaluated by immunohistochemistry. Correlations with clinicopathological characteristics as well as with patient outcome were analyzed.
Results
LXR was frequently localized in both nuclei and cytoplasms of BC cells, with stronger staining in nuclei. Total and nuclear LXR expression was positively correlated with ER and PR status. Overall survival analysis demonstrated that cytoplasmic LXR was significantly correlated with poor survival and appeared as an independent marker of poor prognosis, in stage I but not in stage II–III tumors
Conclusion
Altogether, these data suggest that cytoplasmic LXR could be defined as a prognostic marker in early stage primary BC.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-021-03670-y</identifier><identifier>PMID: 34085098</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Breast cancer ; Cancer Research ; Hematology ; Immunohistochemistry ; Internal Medicine ; Life Sciences ; Liver X receptors ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncology ; Original Article – Cancer Research ; Original – Cancer Research ; Prognosis ; Survival analysis ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2021-09, Vol.147 (9), p.2535-2544</ispartof><rights>The Author(s) 2021. corrected publication 2021</rights><rights>The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>The Author(s) 2021, corrected publication 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133</citedby><cites>FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133</cites><orcidid>0000-0003-2623-3235 ; 0000-0002-7160-3074</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03358570$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Shao, Wanting</creatorcontrib><creatorcontrib>Kuhn, Christina</creatorcontrib><creatorcontrib>Mayr, Doris</creatorcontrib><creatorcontrib>Ditsch, Nina</creatorcontrib><creatorcontrib>Kailuwait, Magdalena</creatorcontrib><creatorcontrib>Wolf, Verena</creatorcontrib><creatorcontrib>Harbeck, Nadia</creatorcontrib><creatorcontrib>Mahner, Sven</creatorcontrib><creatorcontrib>Jeschke, Udo</creatorcontrib><creatorcontrib>Cavaillès, Vincent</creatorcontrib><creatorcontrib>Sixou, Sophie</creatorcontrib><title>Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer (BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival.
Methods
In a well-characterized cohort of 305 primary BC, subcellular distribution of LXR was evaluated by immunohistochemistry. Correlations with clinicopathological characteristics as well as with patient outcome were analyzed.
Results
LXR was frequently localized in both nuclei and cytoplasms of BC cells, with stronger staining in nuclei. Total and nuclear LXR expression was positively correlated with ER and PR status. Overall survival analysis demonstrated that cytoplasmic LXR was significantly correlated with poor survival and appeared as an independent marker of poor prognosis, in stage I but not in stage II–III tumors
Conclusion
Altogether, these data suggest that cytoplasmic LXR could be defined as a prognostic marker in early stage primary BC.</description><subject>Breast cancer</subject><subject>Cancer Research</subject><subject>Hematology</subject><subject>Immunohistochemistry</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Liver X receptors</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article – Cancer Research</subject><subject>Original – Cancer Research</subject><subject>Prognosis</subject><subject>Survival analysis</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9Uk2P0zAQtRCILYU_wMkSFzgE_BHHzgVpVS27SJWQEEjcLNeZtFlSO9jpLvn3TEgFYg9cxpqZ957H40fIS87ecsb0u8xYKUXBBC-YrDQrpkdkxecSl1I9JivGNS-U4NUFeZbzLcNcafGUXMiSGcVqsyLTZhrj0Lt87DzdfvtM4eeQIOcuBtpl6jCGBgbAEEZ6dOk7JBpbOsSY6JDiPsSMuHbO3NghKNP7bjxQcKmfaB7dHhDXIXOiuwQuj9S74CE9J09a12d4cT7X5OuHqy-bm2L76frj5nJb-NKosdhVui4V87xqoC7LWjSVdKLyXLiGgdMMX1WZFrCvhDECytYJ5z1ItdM1LmJN3i-6w2l3hMbjiMn19jyTja6z_3ZCd7D7eGeN5MzIGgXeLAKHB7Sby62dawy3bZRmdxyxr8-XpfjjBHm0xy576HsXIJ6yFUrqqhQcP25NXj2A3sZTCrgKRKnS1JXWs6BYUD7FnBO0fybgzM4usIsLLLrA_naBnZAkF1JGcNhD-iv9H9YvvGm1Vw</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Shao, Wanting</creator><creator>Kuhn, Christina</creator><creator>Mayr, Doris</creator><creator>Ditsch, Nina</creator><creator>Kailuwait, Magdalena</creator><creator>Wolf, Verena</creator><creator>Harbeck, Nadia</creator><creator>Mahner, Sven</creator><creator>Jeschke, Udo</creator><creator>Cavaillès, Vincent</creator><creator>Sixou, Sophie</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2623-3235</orcidid><orcidid>https://orcid.org/0000-0002-7160-3074</orcidid></search><sort><creationdate>20210901</creationdate><title>Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer</title><author>Shao, Wanting ; Kuhn, Christina ; Mayr, Doris ; Ditsch, Nina ; Kailuwait, Magdalena ; Wolf, Verena ; Harbeck, Nadia ; Mahner, Sven ; Jeschke, Udo ; Cavaillès, Vincent ; Sixou, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Breast cancer</topic><topic>Cancer Research</topic><topic>Hematology</topic><topic>Immunohistochemistry</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Liver X receptors</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article – Cancer Research</topic><topic>Original – Cancer Research</topic><topic>Prognosis</topic><topic>Survival analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shao, Wanting</creatorcontrib><creatorcontrib>Kuhn, Christina</creatorcontrib><creatorcontrib>Mayr, Doris</creatorcontrib><creatorcontrib>Ditsch, Nina</creatorcontrib><creatorcontrib>Kailuwait, Magdalena</creatorcontrib><creatorcontrib>Wolf, Verena</creatorcontrib><creatorcontrib>Harbeck, Nadia</creatorcontrib><creatorcontrib>Mahner, Sven</creatorcontrib><creatorcontrib>Jeschke, Udo</creatorcontrib><creatorcontrib>Cavaillès, Vincent</creatorcontrib><creatorcontrib>Sixou, Sophie</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shao, Wanting</au><au>Kuhn, Christina</au><au>Mayr, Doris</au><au>Ditsch, Nina</au><au>Kailuwait, Magdalena</au><au>Wolf, Verena</au><au>Harbeck, Nadia</au><au>Mahner, Sven</au><au>Jeschke, Udo</au><au>Cavaillès, Vincent</au><au>Sixou, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><date>2021-09-01</date><risdate>2021</risdate><volume>147</volume><issue>9</issue><spage>2535</spage><epage>2544</epage><pages>2535-2544</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
The aim of this study was to investigate the expression of liver X receptors α/β (LXR) in primary breast cancer (BC) tissues and to analyze its correlations with clinicopathological parameters including patient survival.
Methods
In a well-characterized cohort of 305 primary BC, subcellular distribution of LXR was evaluated by immunohistochemistry. Correlations with clinicopathological characteristics as well as with patient outcome were analyzed.
Results
LXR was frequently localized in both nuclei and cytoplasms of BC cells, with stronger staining in nuclei. Total and nuclear LXR expression was positively correlated with ER and PR status. Overall survival analysis demonstrated that cytoplasmic LXR was significantly correlated with poor survival and appeared as an independent marker of poor prognosis, in stage I but not in stage II–III tumors
Conclusion
Altogether, these data suggest that cytoplasmic LXR could be defined as a prognostic marker in early stage primary BC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34085098</pmid><doi>10.1007/s00432-021-03670-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2623-3235</orcidid><orcidid>https://orcid.org/0000-0002-7160-3074</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2021-09, Vol.147 (9), p.2535-2544 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8310839 |
| source | Springer Nature |
| subjects | Breast cancer Cancer Research Hematology Immunohistochemistry Internal Medicine Life Sciences Liver X receptors Medical prognosis Medicine Medicine & Public Health Oncology Original Article – Cancer Research Original – Cancer Research Prognosis Survival analysis Tumors |
| title | Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A01%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoplasmic%20LXR%20expression%20is%20an%20independent%20marker%20of%20poor%20prognosis%20for%20patients%20with%20early%20stage%20primary%20breast%20cancer&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Shao,%20Wanting&rft.date=2021-09-01&rft.volume=147&rft.issue=9&rft.spage=2535&rft.epage=2544&rft.pages=2535-2544&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-021-03670-y&rft_dat=%3Cproquest_pubme%3E2537642104%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-b679450c16de94492d63a26c12ad0ea7000168fe16d52882e4fa2acce35b79133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2554896771&rft_id=info:pmid/34085098&rfr_iscdi=true |